These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 27098822

  • 1. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
    Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M, AIDA consortium.
    BMJ Open; 2016 Apr 20; 6(4):e009956. PubMed ID: 27098822
    [Abstract] [Full Text] [Related]

  • 2. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.
    Lancet Infect Dis; 2018 Apr 20; 18(4):391-400. PubMed ID: 29456043
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial.
    Rosso-Fernández C, Garnacho-Montero J, Antonelli M, Dimopoulos G, Cisneros JM, MagicBullet study group.
    Trials; 2015 Mar 20; 16():102. PubMed ID: 25872790
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD.
    Lancet Infect Dis; 2021 Feb 20; 21(2):226-240. PubMed ID: 33058795
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL.
    Trials; 2015 Jan 27; 16():24. PubMed ID: 25623485
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME.
    Antimicrob Agents Chemother; 2005 Aug 27; 49(8):3136-46. PubMed ID: 16048915
    [Abstract] [Full Text] [Related]

  • 8. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.
    Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, De Pascale G, Jiménez-Jorge S, Fernández-Hinojosa E, Matthaiou DK, Ramírez P, Díaz-Miguel RO, Estella A, Antonelli M, Dimopoulos G, Garnacho-Montero J, Magic Bullet Working Group WP1.
    Crit Care; 2019 Nov 28; 23(1):383. PubMed ID: 31779711
    [Abstract] [Full Text] [Related]

  • 9. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C, Sojo-Dorado J, Barriga A, Lavín-Alconero L, Palacios Z, López-Hernández I, Merino V, Camean M, Pascual A, Rodríguez-Baño J, FOREST Study Group.
    BMJ Open; 2015 Mar 31; 5(3):e007363. PubMed ID: 25829373
    [Abstract] [Full Text] [Related]

  • 10. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
    Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y, AIDA Study Group.
    Clin Microbiol Infect; 2020 Sep 31; 26(9):1185-1191. PubMed ID: 32251844
    [Abstract] [Full Text] [Related]

  • 11. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I, Gutiérrez-Gutiérrez B, Gracia-Ahufinger I, Rivera Espinar F, Cano Á, Guzmán-Puche J, Pérez-Nadales E, Natera C, Rodríguez M, León R, Castón JJ, Rodríguez-López F, Rodríguez-Baño J, Torre-Cisneros J.
    Antimicrob Agents Chemother; 2017 Aug 31; 61(8):. PubMed ID: 28559247
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
    Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW.
    Antimicrob Agents Chemother; 2016 Jan 31; 60(1):431-6. PubMed ID: 26525802
    [Abstract] [Full Text] [Related]

  • 15. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG, Shah SR.
    J Assoc Physicians India; 2015 Jul 31; 63(7):14-8. PubMed ID: 26731822
    [Abstract] [Full Text] [Related]

  • 16. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P, Kiratisin P, Thamlikitkul V.
    J Med Assoc Thai; 2010 Jan 31; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [Abstract] [Full Text] [Related]

  • 17. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
    Yilmaz GR, Guven T, Guner R, Kocak Tufan Z, Izdes S, Tasyaran MA, Acikgoz ZC.
    J Infect Dev Ctries; 2015 May 18; 9(5):476-85. PubMed ID: 25989167
    [Abstract] [Full Text] [Related]

  • 18. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
    Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, Yahav D, Eliakim-Raz N, Carmeli Y, Nutman A, Paul M, AIDA Study Group.
    Clin Infect Dis; 2018 Nov 28; 67(12):1815-1823. PubMed ID: 29718143
    [Abstract] [Full Text] [Related]

  • 19. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis.
    Gu WJ, Wang F, Tang L, Bakker J, Liu JC.
    Int J Antimicrob Agents; 2014 Dec 28; 44(6):477-85. PubMed ID: 25199968
    [Abstract] [Full Text] [Related]

  • 20. Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens.
    Yılmaz GR, Baştuğ AT, But A, Yıldız S, Yetkin MA, Kanyılmaz D, Akıncı E, Bodur H.
    J Infect Chemother; 2013 Feb 28; 19(1):57-62. PubMed ID: 22806446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.